FindTrial
Sign In

Combined External- Endoscopic Endonasal Assisted En bloc Resection of Malignant Tumors from the Lacrimal Drainage System: a case records based study

Retrospective study for Combined External- Endoscopic Endonasal Assisted En bloc Resection of Malignant Tumors from the Lacrimal Drainage System

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-17013153
Enrollment
Unknown
Registered
2017-10-30
Start date
2017-11-15
Completion date
Unknown
Last updated
2017-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tumors from the Lacrimal Drainage System

Interventions

one:surgery

Sponsors

Eye Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
38 Years to 66 Years

Inclusion criteria

Inclusion criteria: 1. diagnose with tumors from the Lacrimal Drainage System; 2. confirmed diagnosis with CT and MRI.;Inclusion criteria: 1. diagnose with tumors from the Lacrimal Drainage System; 2. confirmed diagnosis with CT and MRI.;Inclusion criteria: 1. diagnose with tumors from the Lacrimal Drainage System; 2. confirmed diagnosis with CT and MRI.;Inclusion criteria: 1. diagnose with tumors from the Lacrimal Drainage System; 2. confirmed diagnosis with CT and MRI.;Inclusion criteria: 1. diagnose with tumors from the Lacrimal Drainage System; 2. confirmed diagnosis with CT and MRI.

Exclusion criteria

Exclusion criteria: 1. Exclude metastatic tumors; 2. Exclude other diseases of the Lacrimal Drainage System.;Exclusion criteria: 1. Exclude metastatic tumors; 2. Exclude other diseases of the Lacrimal Drainage System.;Exclusion criteria: 1. Exclude metastatic tumors; 2. Exclude other diseases of the Lacrimal Drainage System.;Exclusion criteria: 1. Exclude metastatic tumors; 2. Exclude other diseases of the Lacrimal Drainage System.;Exclusion criteria: 1. Exclude metastatic tumors; 2. Exclude other diseases of the Lacrimal Drainage System.

Design outcomes

Primary

MeasureTime frame
recurrence of tumor;—

Countries

China

Contacts

Public ContactJieliang Shi;Jieliang Shi;Jieliang Shi;Jieliang Shi;Jieliang Shi ;;;;

Eye Hospital of Wenzhou Medical University;Eye Hospital of Wenzhou Medical University;Eye Hospital of Wenzhou Medical University;Eye Hospital of Wenzhou Medical University;Eye Hospital of Wenzhou Medical University

ysgxsjl@126.com;ysgxsjl@126.com;ysgxsjl@126.com;ysgxsjl@126.com;ysgxsjl@126.com+86 15867751952;+86 15867751952;+86 15867751952;+86 15867751952;+86 15867751952

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026